Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1787400 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $2.54 · Day +5.39% · Mkt cap $173M · 1Y +10.4% · Off 52W high −31.7% · Vol (1Y) 74.5% Price2023-08-21 → 2026-08-19 NKTX close: $1.8 on 2023-08-21 to $2.5 on 2026-08-19. Split-adj closes · 240 of 1,375 · price returnⓘ At a glance | Short interest4.6% of sh out | | Days to cover5.3d | | 13F net flow (QoQ)+4.32% | | Top-10 13F concentration65.1% | | Next report (est.)2026-11-08 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$0 | | Earnings (TTM)-$117.3M | | ROE−28.9% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+37.3% | | 1Y+10.4% | | 3Y+39.6% | | 5Y−92.3% | | Since incept. (ann.)−43.1% |
Total return · from 2021-02-22ⓘ Risk | Ann. volatility (1Y)74.5% | | Ann. volatility (3Y)119.6% | | Sharpe (1Y)0.47 | | Sharpe (3Y)0.58 | | Max drawdown (1Y)−43.1% | | Max drawdown (3Y)−91.3% | | Beta (3Y vs SPY)2.96 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| RA CAPITAL MANAGEMENT, L.P. | 10.8M | $23M | 15.16% | +0.0% | | BlackRock, Inc. | 4.5M | $10M | 6.32% | +9.6% | | NEA Management Company, LLC | 3.6M | $8M | 5.01% | +0.0% | | SAMSARA BIOCAPITAL, LLC | 3.5M | $7M | 4.92% | +0.0% | | SR One Capital Management, LP | 3.3M | $7M | 4.68% | +0.0% | | GSK plc | 3.2M | $7M | 4.42% | +0.0% | | Monaco Asset Management SAM | 2.5M | $5M | 3.54% | −1.0% | | Alyeska Investment Group, L.P. | 2.1M | $4M | 2.92% | +0.0% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-10 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-10 | −$0.54 | — | — | — | | 2026-03-31 | 2026-05-12 | −$0.37 | — | — | — | | 2025-09-30 | 2025-11-10 | −$0.29 | — | — | — | | 2025-06-30 | 2025-08-12 | −$0.31 | — | — | — |
As-reported XBRL · next 2026-11-08 est.ⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
|
